mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults (NCT07557602) | Clinical Trial Compass
Not Yet RecruitingPhase 1
mRNA Vaccine Targeting Epstein-Barr Virus (EBV) in Healthy Young Adults
Australia45 participantsStarted 2026-05-04
Plain-language summary
This is an adaptive design Phase 1 clinical trial to evaluate the safety and immunogenicity of VXCO-102 in healthy adult participants.
Who can participate
Age range
18 Years – 25 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Aged 18 to 25 years, inclusive
* Healthy per medical assessment based on self-reported medical history, physical examination, vital signs, and laboratory assessment
Exclusion Criteria:
* Self-reported or medically-documented significant medical or psychiatric condition that per medical assessment could interfere with study participation
* Likely or confirmed myocarditis or pericarditis
* Prior receipt of an investigational EBV vaccine
* Prior receipt of a licensed vaccine within 56 days prior to Day 1
* Received more than 10 days of any systemic immunosuppressants or cytotoxic medications within 56 days prior to Day 1, any within 14 days prior to Day 1, or will need immunosuppressants at any time during the study.
* For participants of childbearing potential: pregnant, breastfeeding or planning to become pregnant during the study
Note: Other inclusion and exclusion criteria apply.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of Participants with Solicited Local and Systemic Reactions
Timeframe: 7 days after each product administration
2
Number of Participants with Unsolicited Adverse Events
Timeframe: Up to 28 days after each product administration
3
Number of Participants with Serious Adverse Events (SAEs) including Suspected Unexpected Serious Adverse Reactions (SUSARs) and Adverse Events of Special Interest (AESIs)